Glaucoma

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.

Patients with HTG had significantly fewer mtDNA copies per nuclear DNA.

According researchers at the University of Gothenburg, for patients who recently received a diagnosis, discovery of glaucoma could mean they start treatment with daily eye drops that lower the pressure in the eye and slow down the damage to the optic nerve.

The trial is for the MINIject MIGS device for patients with primary open-angle glaucoma.

The system is a next generation aqueous shunt therapy for patients with moderate to severe glaucoma.

Brimonidine is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

TRS01 demonstrates clear anti-inflammatory activity in noninfectious anterior uveitis with no evidence of significant adverse effects.

Santen will receive an equity stake in Visiox as an upfront payment, and remains eligible to receive sales milestone payments, as well as royalties on net sales of omidenepag isopropyl ophthalmic solution in the United States.

According to the company, the financing will advance novel treatments for glaucoma and other chronic ophthalmic diseases by supporting multiple US clinical trials of its drug delivery platform.

The second issue of the 2023 Video Journal of Cataract, Refractive, & Glaucoma Surgery offers a compilation of 27 surgical highlights from the ESCRS meeting in Milan, providing valuable education for global anterior segment surgeons.

The company announced its contract manufacture, NextPharma, completed filling of the drug materials into strips of 10 single-use vials for use in upcoming glaucoma trial.

Procedures in the pipeline hold greater appeal for cataract and refractive surgeons, patients.

The company seeks to replicate European success of the ELIOS procedure in the US market.

The funds will be used to further develop the company’s Calibreye System that aims to optimize reduction of intraocular pressure (IOP) for patients with moderate to advanced glaucoma.

According to researchers, the study is the first to assess associations between pre-diagnostic circulating metabolites and POAG risk in two large independent datasets.

Cigna’s Coverage Policy includes procedures enabled with OMNI® Surgical System technology as medically necessary and covered.

The study results could help lead to improved understanding of glaucoma and new therapies.

SBI-100 is a cannabinoid receptor type 1 (CB1R) agonist administered topically onto the eye to reduce IOP and treat glaucoma.

Elaine Ye Wang, MD, discusses the MicroPulse TLT and the benefits the procedure because it does not require patients to alter their lifestyle.

Elaine Ye Wang, MD, discusses adapting transscleral laser therapy (TLT) using MicroPulse technology into her practice and the benefits of using the technique.

The ophthalmic solution from VivaVision is being studied for the treatment of glaucoma.

The event is a forum for the exchange of ideas between leading scientists in diverse fields to bring their knowledge to the challenges of glaucoma and help set the course for future glaucoma research.

Therapeutic has fewer adverse effects in patients with POAG, OHT.

The project, a collaboration with researchers from the University of Maryland, holds promise for advancing new and more tolerable drug treatments for common chronic blinding eye diseases, including glaucoma and macular degeneration.

SLT shows promise as treatment for millions of Africans with glaucoma.

Louis R. Pasquale, MD, FARVO, will be presented the award by previous winner Robert N. Weinreb, MD.

According to the company, study results show sustained reductions in both IOP and glaucoma medication use in mild-moderate primary open angle glaucoma patients treated with a procedure enabled with the OMNI Surgical System technology.

Debate continues over the best way to apply the treatment option.

According to the company, a PDUFA date has been set for December 22, 2023.

The study, titled “A Clinical Registry Study of Glaucoma Medication Use in Patients with Mild Glaucoma Severity After MIGS,” will be presented Sunday by Michael Mbagwu, MD, at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, California.